OncoMatch/Clinical Trials/NCT07745361
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Is NCT07745361 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Oral MRT-2359 and Apalutamide for castration-resistant prostate cancer (crpc).
Treatment: Oral MRT-2359 · Apalutamide — This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: AR mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: androgen receptor pathway inhibitor
Has received prior treatment with at least 1 line of ARPi
Cannot have received: taxane-based chemotherapy
Exception: no more than 1 prior regimen for castration-resistant prostate cancer
Have not had prior treatment with more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer
Cannot have received: AR degrader
Have no prior treatment with an AR degrader, opevesostat, or similar therapy
Cannot have received: GSPT1 degrader
Exception: only if discontinued due to an AE
Have received prior therapy with a GSPT1 degrader that was discontinued due to an AE
Cannot have received: autologous hematopoietic cell transplant
Exception: unless fully recovered from effects of last transplant
Have received prior auto-HCT and have not fully recovered from effects of the last transplant
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within past 6 months and/or have symptoms of graft-versus-host disease
Have received allogeneic hematopoietic stem cell transplantation within past 6 months and/or have symptoms of graft-versus-host disease
Lab requirements
Blood counts
Kidney function
Liver function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START Los Angeles · Los Angeles, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
- Rocky Mountain Cancer Center · Colorado Springs, Colorado
- Kansas University Cancer Center · Kansas City, Kansas
- University of Maryland Greenebaum Cancer Center · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07745361 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior taxane-based chemotherapy, AR degrader, GSPT1 degrader disqualifies patients from enrollment.
Does this trial require AR?
Yes, AR mutation is a required biomarker for enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages